Organon (OGN) Q3 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 10/31/24
Ahead of Organon (OGN) Q3 Earnings: Get Ready With Wall Street Estimates for Key MetricsZacks Investment Research • 10/28/24
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%Business Wire • 10/28/24
Want $300 in Dividends Every Month? Invest $20,000 in Each of These 3 StocksThe Motley Fool • 10/24/24
Organon (OGN) Loses -9.91% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 10/09/24
Organon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024Business Wire • 10/09/24
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%Business Wire • 09/18/24
JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of StabilityBenzinga • 09/06/24
Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional MarketsBusiness Wire • 08/20/24
Organon (OGN) Q2 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 08/06/24
Seeking Clues to Organon (OGN) Q2 Earnings? A Peek Into Wall Street Projections for Key MetricsZacks Investment Research • 08/01/24